This study is for patients 75 years or older with a type of cancer called diffuse large B cell lymphoma (DLBCL). It tests if adding a new drug, CC-486 (oral azacitidine), to a usual cancer treatment called R-miniCHOP helps patients live longer or feel better. R-miniCHOP is a mix of medicines: rituximab (helps the immune system fight cancer), prednisone (reduces swelling), and three chemotherapy drugs (cyclophosphamide, doxorubicin, vincristine) to stop cancer growth. The study will check if CC-486 makes the treatment too harmful and if it helps patients more than R-miniCHOP alone. Patients will either get R-miniCHOP with CC-486 or just R-miniCHOP. They will receive treatments in cycles every 21 days and be monitored for up to 5 years. Before joining, patients must meet certain health conditions, like having controlled infections and good heart health.
- The study lasts for several months with follow-ups for up to 5 years.
- Patients will have regular blood tests and health checks.
- Potential risks include side effects from the drugs used.